SchizophreniaNCT01769014
Adherence and Quality of Life in People With Schizophrenia and Schizoaffective Disorder
An observational study of Schizophrenia and Schizoaffective Disorder, run by Psychiatrische Dienste Graubuenden at 1 site in Switzerland.
Trial summary
It is the goal of this study adherence and quality of life in a population of people suffering from schizophrenia or schizoaffective disorder and to analyze if these factors are influenced by treatment, support, social services, and residential treatment. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Schizophrenia, Schizoaffective Disorder, Quality of Life
- How many people
- 100 participants
- Where
- 1 siteSwitzerland
- Study dates
- Jan 2013to Dec 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: People who suffer from schizophrenia or schizoaffective disorder, following DSM IV criteria and who live in the cantons Glarus, Graubuenden or the Principality of Liechtenstein.
Who may be able to join
- Schizophrenia or schizoaffective disorder
- 18 - 65 years old
- treated in the PDGR within the past 19 years
Who cannot join
- organic brain disorder
- alcohol or drug dependence
- low intelligence
- unable to give consent
- no legal competency
- lacking knowledge of German language
- current psychiatric inpatient treatment
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Psychiatrische Dienste Graubuenden
St. Moritz, Kanton Graubünden, 7500
About this study
Official title: In the Cantons Graubunden and Glarus as Well as in the Principality of Liechtenstein: Influence of Intensive Outpatient Treatment of People With Schizophrenia and Schizoaffective Disorder on Quality of Life and Adherence
It is the goal of this study adherence and quality of life in a population of people suffering from schizophrenia or schizoaffective disorder and to analyze if these factors are influenced by treatment, support, social services, and residential treatment. The study population is drawn from the the cantons Glarus and Graubunden as well as Liechtenstein.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Quality of Life
- Keywords
- adherence
- Medical subject headings
- Schizophrenia, Psychotic Disorders
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of life
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2013 (estimated)
- Study startJan 2013
- Primary completionApr 2013 (estimated)
- Study completionDec 2013 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Psychiatrische Dienste Graubuenden
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01769014
- Sponsor's protocol ID
- KEK-ZH-Nr.2012-0178
- Status last verified
- Jan 2013
- First submitted
- 14 Jan 2013
- Last updated
- 16 Jan 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- In the Cantons Graubunden and Glarus as Well as in the Principality of Liechtenstein: Influence of Intensive Outpatient Treatment of People With Schizophrenia and Schizoaffective Disorder on Quality of Life and Adherence
- ClinicalTrials.gov ID
- NCT01769014
- Acronym / sponsor ID
- KEK-ZH-Nr.2012-0178
- Conditions
- Schizophrenia, Schizoaffective Disorder, Quality of Life
- Keywords
- adherence
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Psychiatrische Dienste GraubuendenUniversity, hospital or other
- Study start
- Jan 2013
- Primary completion
- Apr 2013 (estimated)
- Study completion
- Dec 2013 (estimated)
- First posted
- 16 Jan 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is the goal of this study adherence and quality of life in a population of people suffering from schizophrenia or schizoaffective disorder and to analyze if these factors are influenced by treatment, support, social services, and residential treatment. The study population is drawn from the the cantons Glarus and Graubunden as well as Liechtenstein.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- People who suffer from schizophrenia or schizoaffective disorder, following DSM IV criteria and who live in the cantons Glarus, Graubuenden or the Principality of Liechtenstein.
Key inclusion criteria (3 listed)
- Schizophrenia or schizoaffective disorder
- 18 - 65 years old
- treated in the PDGR within the past 19 years
Key exclusion criteria (7 listed)
- organic brain disorder
- alcohol or drug dependence
- low intelligence
- unable to give consent
- no legal competency
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Quality of life
Time frame: 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2013.
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
Treatment Resistant Disorders
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Schizophrenia and Schizoaffective Disorder, run by Psychiatrische Dienste Graubuenden at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of life (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2013.